



























































The Efficacy of Cannabidiol in the Treatment of 
Anxiety Disorders 
The	results	of	this	study	support	that	CBD	is	an	efficacious	
treatment	for	anxiety	provoking	situa6ons.	For	individuals	
who	do	not	find	relief	with	current	first-line	treatments	or	
are	looking	for	a	more	favorable	side-effect	profile,	CBD	
should	be	considered	as	an	alterna6ve.		
CBD	seems	more	effec6ve	currently	for	episodic	anxiety	
provoking	situa6ons,	and	more	research	is	necessary	to	
iden6fy	if	CBD	is	a	viable	op6on	for	daily	use	in	the	
treatment	of	chronic	anxiety.	Addi6onally,	CBD	will	likely	be	
more	efficacious	when	used	in	combina6on	with	CBT,	like	
many	of	the	current	first	line	treatment	op6ons.		
Conclusion	
There	is	suppor6ve	evidence	that	cannabidiol	may	be	efficacious	in	reducing	symptoms	
of	anxiety	disorders	and	symptoms	in	adults.	Six	RCTs	analyzed	the	efficacy	of	CBD	in	
reducing	anxiety	symptoms	in	different	anxiety	provoking	situa6on	ranging	including	
public	speaking,	laboratory	tes6ng,	and	virtual	reality	situa6ons.	Doses	of	CBD	varied,	
but	five	of	the	six	RCTs	supported	that	CBD	is	an	efficacious	treatment	op6ons	for	anxiety	
in	short-term	anxiety	provoking	situa6ons,	with	minimal	side	effects	experienced	from	
CBD.	Furthermore,	two	of	the	studies	(Crippa	et	al,	2011	&	Fusar-Poli	et	al,	2009)	found	
significant	differences	in	brain	imaging	of	the	CBD	treated	individuals	and	placebo	
treated	individuals	when	involved	in	the	anxiety-provoking	situa6ons.		Hundal	et	al	
(2018)	found	that	the	group	that	ingested	CBD	prior	to	the	anxiety	provoking	situa6on	
experienced	an	increase	in	anxiety,	although	not	sta6s6cally	significant.	Overall,	there	
was	strong	support	for	the	anxioly6c	proper6es	of	CBD	as	shown	in	five	of	the	six	studies	
with	both	subjec6ve	and	objec6ve	measures.	
Overview	
Anxiety	disorders	are	typically	chronic,	requiring	lifelong	amen6on	and	treatment.	
Account	for	1.7	million	Total	Years	Lived	with	Disability	(YLD),	nearly	5%	of	the	
U.S.’s	total	YLD.	
Anxiety	disorders	in	this	study	include	generalized	anxiety	disorder,	panic	
disorder,	and	social	anxiety	disorder.	
Current	treatments	
First	line	treatments:	
•  Cogni6ve	Behavioral	Therapy	(CBT)	
•  Selec6ve	serotonin	reuptake	inhibitors	(SSRIs)	
•  Serotonin-norepinephrine	reuptake	inhibitors	(SNRIs)	
•  Benzodiazepines	
•  Beta-blockers	
33-50%	of	pa6ents	do	not	experience	sustained	remission	from	anxiety	with	use	
of	a	SSRI	or	SNRI.	
Benzodiazepines	have	poten6al	for	physiological	dependence	and	rebound	
anxiety	upon	discon6nua6on.	
Study	 Sample	Size	 Anxiety	
disorder	
IntervenHon	 Tx	Regimen	 ObjecHve	
Measures	
SubjecHve	
Measures	
Bergamaschi	
et	al,	2011	
36	 Social	anxiety	
disorder	
Simulated	
public	
speaking	
600	mg	oral	
CBD,	once	
Significant	 Significant	
Crippa	et	al,	
2011	
10	 Social	anxiety	
disorder	
Neuroimaging	 400	mg	oral	
CBD,	once	
Significant	 Significant	
Das	et	al,	2013	 48	 Condi6oned	
fear	
Fear	
condi6oning	
paradigm	
32	mg	of	
inhaled	CBD,	
once	
Significant*	 Insignificant	
Fusar-Poli,	
2009	
15	 None	 Processing	of	
facial	
expressions	
with	
func6onal	MRI	
600	mg	oral	
CBD	or	10	mg	
of	THC,	once	
Significant	 Insignificant	
Hundal	et	al,	
2018	
32	 High	trait	
paranoid	
group	–	
Generalized	
anxiety	
disorder	
Virtual	reality	
anxiety	
provoking	
situa6on	–	
London	
underground	
train	
600	mg	oral	
CBD,	once	
Insignificant	 Insignificant	
Zuardi	et	al,	
2017	
60	 None	 Public	
speaking	in	
real	situa6on	
100,	300,	or	
900	mg	oral	
CBD,	or	1	mg	
oral	
Clonazepam,	
once	
N/A	 Significant	
Significant	=	p	<	0.05;	*	=	p	<	0.10;	MRI	=	Magne6c	Resonance	Imaging	
